Chemonucleolysis with Chondroitin Sulfate ABC Endolyase for Treating Lumbar Disc Herniation: Exploration of Prognostic Factors for Good or Poor Clinical Outcomes

Background and Objectives: Chondroitin sulfate ABC endolyase (condoliase) was launched as a new drug for chemonucleolysis in 2018. Few studies assessed its clinical outcomes, and many important factors remain unclear. This study aimed to clarify the preoperative conditions in which condoliase could...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishibashi, Katsuhiko, Fujita, Muneyoshi, Takano, Yuichi, Iwai, Hiroki, Inanami, Hirohiko, Koga, Hisashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699387/
https://www.ncbi.nlm.nih.gov/pubmed/33228119
http://dx.doi.org/10.3390/medicina56110627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699387/
https://www.ncbi.nlm.nih.gov/pubmed/33228119
http://dx.doi.org/10.3390/medicina56110627

Ejemplares similares